[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357971-105":59,"doc-detail-357971-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dna-methylation-profiling-enables-subclassification-of-mucinous-ovarian-carcinoma-and-distinguishes-it-from-extraovarian-mucinous-metastases","DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases","","Mucinous ovarian carcinoma (MOC) is often misclassified as extraovarian mucinous metastasis (EOM) due to overlapping features. A genome-wide DNA methylation profiling study of 58 MOCs, 38 EOMs, and 18 mucinous borderline ovarian tumors (mBOTs) identifies two mBOT epigenetic groups and two MOC methylation subtypes with potential prognostic relevance. A three-step machine-learning classifier distinguishes MOC from EOM with 95.5% internal accuracy and 91.11% accuracy in external validation, providing a robust clinical diagnostic tool.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dna-methylation-profiling-enables-subclassification-of-mucinous-ovarian-carcinoma-and-distinguishes-it-from-extraovarian-mucinous-metastases/357971/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dna-methylation-profiling-enables-subclassification-of-mucinous-ovarian-carcinoma-and-distinguishes-it-from-extraovarian-mucinous-metastases/357971.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is DNA methylation profiling used for mucinous ovarian tumors?","Question",{"text":112,"@type":113},"Overlapping histologic features often lead to misclassification of MOC as extraovarian mucinous metastasis (EOM). DNA methylation profiling provides epigenetic patterns to improve diagnostic separation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What epigenetic groups are identified among mucinous borderline ovarian tumors (mBOTs) and MOC?",{"text":117,"@type":113},"Methylation analysis defines two mBOT groups—one epigenetically similar to normal ovary and one resembling MOC. Unsupervised clustering also reveals two distinct MOC methylation subtypes with potential prognostic relevance.",{"name":119,"@type":110,"acceptedAnswer":120},"How accurate is the machine-learning classifier for distinguishing MOC from EOM?",{"text":121,"@type":113},"The three-step classifier achieves 95.5% accuracy in the internal cohort and 91.11% accuracy in external validation (21 MOCs and 24 EOMs).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357971,1790576973,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nDNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases  \nAuthors  \nTeodor G. Calina, Elena Grafenhorst, Simon Schallenberg, ..., Kylie L. Gorringe, David Capper, Mihnea P. Dragomir  \nCorrespondence  \n[mihnea.dragomir@charite.de](mihnea.dragomir@charite.de)  \nIn brief  \nCalina and Grafenhorst et al. using DNA methylation profiling of mucinous ovarian tumors characterize two mucinous ovarian carcinoma (MOC) subgroups with potential differing outcomes and describe epigenetic patterns consistent with the stepwise relationship between mucinous borderline ovarian tumor and MOC. An epigenetic classifier accurately distinguishes MOC from metastases, improving diagnosis.  \n• mBOTs separate into ‘‘normal-like’’ and ‘‘carcinoma-like’’methylation states  \n• Two epigenetic subtypes of MOC suggest differential survival associations  \n• Epigenetic classifier achieves >90% accuracy in separating MOCs from metastases  \nCalina et al., 2026, Cell Reports Medicine 7, 102941  \nAugust 18, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102941](https://doi.org/10.1016/j.xcrm.2026.102941)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nDNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases  \nTeodor G. Calina,1,2,24 Elena Grafenhorst,3,24 Simon Schallenberg,3 Markus M¨obs,3 Bjarne Daenekas,4,5  \nAlexandru A. Sabo,6 BaoQing Chen,7,8 Ines Koch,3 Tobias Janik,3 Michael Churchman,9 Charlie Gourley,9 Elizabeth L. Christie,10,11 Catalin Vasilescu,12 Vlad Herlea,13 Wolfgang D. Schmitt,3 Nicolae Leopold,1 Florian Heitz,14 Angelina Vlaski,15 Yuri Tolkach,16 Felix Bremmer,17 Frederick Klauschen,3,4,15 Reinhard Bu¨ttner,16 Philipp Str¨obel,17 Eike Burandt,18 Guido Sauter,18 Frank L. Heppner,5,19 Eliane T. Taube,3,23 Jalid Sehouli,20,21 Ioana E. Braicu,20,21 Philipp Euskirchen,4,5 David Horst,3,4 Kylie L. Gorringe,10,11 David Capper,4,5 and Mihnea P. Dragomir3,4,22,25,*  \n1Faculty of Physics, Babes‚ -Bolyai University, Cluj-Napoca, Romania  \n2TGC Ventures UG, Berlin, Germany  \n3Institute of Pathology, Charit´e-Universit¨atsmedizin Berlin, Corporate Member of Freie Universit¨at Berlin, Humboldt-Universit¨at zu Berlin, Berlin, Germany  \n4German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany  \n5Department of Neuropathology, Charit´e-Universit¨atsmedizin Berlin, Corporate Member of Freie Universit¨at Berlin, Humboldt-Universit¨at zu Berlin, Berlin, Germany  \n6Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University Children’s Hospital Tu¨bingen, Tu¨bingen, Germany  \n7State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China  \n8Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China  \n9Nicola Murray Centre for Ovarian Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK  \n10The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia  \n11Peter MacCallum Cancer Centre, Melbourne, VIC, Australia  \n12Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania  \n13Department of Pathology, Fundeni Clinical Institute, Bucharest, Romania  \n14Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany  \n15Institute of Pathology, Ludwig-Maximilians-Universit¨at Munich, Munich, Germany  \n16Institute of Pathology, University Hospital Cologne, K¨oln, Germany  \n17Institute of Pathology, University Medical Center Go¨ttingen, Go¨ttingen, Germany  \n18Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany  \n19German Center for Neurodegenerative Diseases (DZNE","cbCaibMIWbq3fcCy","https://ap.wps.com/l/cbCaibMIWbq3fcCy","pdf",7805687,25,"English","# Summary\n## Study design and cohorts\n## Epigenetic subgroups and clustering\n## Classifier development and validation","[{\"question\":\"Why is DNA methylation profiling used for mucinous ovarian tumors?\",\"answer\":\"Overlapping histologic features often lead to misclassification of MOC as extraovarian mucinous metastasis (EOM). DNA methylation profiling provides epigenetic patterns to improve diagnostic separation.\"},{\"question\":\"What epigenetic groups are identified among mucinous borderline ovarian tumors (mBOTs) and MOC?\",\"answer\":\"Methylation analysis defines two mBOT groups—one epigenetically similar to normal ovary and one resembling MOC. Unsupervised clustering also reveals two distinct MOC methylation subtypes with potential prognostic relevance.\"},{\"question\":\"How accurate is the machine-learning classifier for distinguishing MOC from EOM?\",\"answer\":\"The three-step classifier achieves 95.5% accuracy in the internal cohort and 91.11% accuracy in external validation (21 MOCs and 24 EOMs).\"}]","DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases | PDF",1790132393,63]